News-Heavy Day For Several Biotech Stocks

Legal settlements, licensing and drug approvals were among stories Wednesday driving several biotech stocks. •Mayne Pharma MAYNF gained more than 6 percent to 0.72 cents a share after its patent dispute with Pfizer Inc. PFE reached a settlement. Australia-based Mayne expects to enter the U.S. market next year with a generic version of Pfizer's atrial fibrillation treatment Tikosyn. Terms of Mayne's agreement with Pfizer weren't disclosed. Mayne said Tikosyn U.S. sales last year were $150 million. •Myriad Genetics Inc. MYGN jumped nearly 5 percent after the company boosted its stock buyback plan by $200 million. •Aratana Therapeutics Inc. PETX ticked up more than 2 percent Wednesday after the veterinary drug company said it had regained the right to its AT-004 treatment for dog lymphoma. The product obtained U.S. approval last month and had been licensed to Novartis NVS. •Jazz Pharmaceuticals plc JAZZ changed hands recently up nearly 2 percent at $178.11. The shares dipped earlier after Jazz voluntarily suspended patient enrollment in a Phase 2 trial of its leukemia drug, JZP-416, based on negative reactions in some patients. •AbbVie Inc. ABBV and Merck & Co. Inc. MRK were little changed after U.K. drug regulators recommended approval for the companies Remicade and Simponi treatments for ulcerative colitis
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsBuybacksFDALegal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!